المؤلفون: Bhagwat SV; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana. bhagwat_shripad_v@lilly.com., McMillen WT; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Cai S; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Zhao B; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Whitesell M; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Shen W; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Kindler L; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Flack RS; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Wu W; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Anderson B; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Zhai Y; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Yuan XJ; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Pogue M; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Van Horn RD; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Rao X; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., McCann D; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Dropsey AJ; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Manro J; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Walgren J; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Yuen E; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Rodriguez MJ; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Plowman GD; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Tiu RV; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Joseph S; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Peng SB; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.

المصدر: Molecular cancer therapeutics [Mol Cancer Ther] 2020 Feb; Vol. 19 (2), pp. 325-336. Date of Electronic Publication: 2019 Nov 19.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Precision Medicine*, Neoplasms/*drug therapy, Animals ; Disease Models, Animal ; Female ; Humans ; Mice ; Mice, Nude ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use

المؤلفون: Gelbert LM; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA, de_dios_alfonso@lilly.com., Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, Torres R, Ajamie RT, Wishart GN, Flack RS, Neubauer BL, Young J, Chan EM, Iversen P, Cronier D, Kreklau E, de Dios A

المصدر: Investigational new drugs [Invest New Drugs] 2014 Oct; Vol. 32 (5), pp. 825-37. Date of Electronic Publication: 2014 Jun 13.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

مواضيع طبية MeSH: Aminopyridines/*pharmacology , Antineoplastic Agents/*pharmacology , Benzimidazoles/*pharmacology , Cyclin-Dependent Kinase 4/*antagonists & inhibitors , Cyclin-Dependent Kinase 6/*antagonists & inhibitors , Protein Kinase Inhibitors/*pharmacology, Aminopyridines/therapeutic use ; Animals ; Antineoplastic Agents/therapeutic use ; Benzimidazoles/therapeutic use ; Cell Line, Tumor ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; Drug Therapy, Combination ; Female ; G1 Phase Cell Cycle Checkpoints/drug effects ; Humans ; Mice ; Neoplasms/drug therapy ; Neoplasms/metabolism ; Neoplasms/pathology ; Phosphorylation/drug effects ; Protein Kinase Inhibitors/therapeutic use ; Retinoblastoma Protein/antagonists & inhibitors ; Retinoblastoma Protein/metabolism ; Tumor Burden/drug effects ; Xenograft Model Antitumor Assays ; Gemcitabine